Enhanced phosphorylation of the epidermal growth factor receptor at the site of tyrosine 992 in esophageal carcinomas

APMIS

Volumn 116, Issue 12, 2008, Pages 1097-1106

  Miyawaki, Michiyo ^a   Hijiya, Naoki ^a   Tsukamoto, Yoshiyuki ^a   Nakada, Chisato ^a   Kawahara, Katsunobu ^a   Moriyama, Masatsugu ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Autophosphorylation; EGFR; Esophageal carcinoma; Tyrosine kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PARAFFIN; POLYCLONAL ANTIBODY; TYROSINE;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; CARCINOMA; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TYROSINE;

EID: 58149201285     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2008.01125.x     Document Type: Article

References (33)

1. th ed. New York : McGraw-Hill Medical Publishing, 2004.
2. Morita M, Yoshida R, Ikeda K, Egashira A, Oki E, Sadanaga N, et al. Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. Surgery 2008 143 : 499 508.
3. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005 93 : 107 15.
4. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006 118 : 1173 80.
5. Hendler FJ, Ozanne BW. Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest 1984 74 : 647 51.
6. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994 74 : 795 804.
7. Mukaida H, Toi M, Hirai T, Yamashita Y, Toge T. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 1991 68 : 142 8.
8. Yano H, Shiozaki H, Kobayashi K, Yano T, Tahara H, Tamura S, et al. Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma. Cancer 1991 67 : 91 8.
9. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004 306 : 1506 7.
10. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001 37 (Suppl S3 8.
11. Nogami M, Yamazaki M, Watanabe H, Okabayashi Y, Kido Y, Kasuga M, et al. Requirement of autophosphorylated tyrosine 992 of EGF receptor and its docking protein phospholipase C gamma 1 for membrane ruffle formation. FEBS Lett 2003 536 : 71 6.
12. Sobin LH, Wittekind CH. UICC: TNM Classification of Malignant Tumors, 6th ed. New York : Wiley-Liss, 2002.
13. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002 8 : 3250 8.
14. Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, et al. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 2002 98 : 463 9.
15. Hara F, Aoe M, Doihara H, Taira N, Shien T, Takahashi H, et al. Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett 2005 226 : 37 47.
16. Janne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002 62 : 5242 7.
17. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000 6 : 4885 92.
18. Ozawa S, Ueda M, Ando N, Abe O, Shimizu N. High incidence of EGF receptor hyperproduction in esophageal squamous-cell carcinomas. Int J Cancer 1987 39 : 333 7.
19. Hsuan JJ, Totty N, Waterfield MD. Identification of a novel autophosphorylation site (P4) on the epidermal growth factor receptor. Biochem J 1989 262 : 659 63.
20. Margolis BL, Lax I, Kris R, Dombalagian M, Honegger AM, Howk R, et al. All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. J Biol Chem 1989 264 : 10667 71.
21. Walton GM, Chen WS, Rosenfeld MG, Gill GN. Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates. J Biol Chem 1990 265 : 1750 4.
22. Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Baron AE, et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2005 131 : 111 9.
23. Carneiro A, Isinger A, Karlsson A, Johansson J, Jonsson G, Bendahl PO, et al. Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer. BMC Cancer 2008 8 : 98.
24. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005 5 : 341 54.
25. Laskin JJ, Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 2004 30 : 1 17.
26. Wells A, Kassis J, Solava J, Turner T, Lauffenburger DA. Growth factor-induced cell motility in tumor invasion. Acta Oncol 2002 41 : 124 30.
27. Rotin D, Margolis B, Mohammadi M, Daly RJ, Daum G, Li N, et al. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma. Embo J 1992 11 : 559 67.
28. Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, et al. SH2 domains recognize specific phosphopeptide sequences. Cell 1993 72 : 767 78.
29. Chen P, Xie H, Sekar MC, Gupta K, Wells A. Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol 1994 127 : 847 57.
30. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992 70 : 401 10.
31. Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J, et al. Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res 2003 63 : 5629 35.
32. Baugher PJ, Krishnamoorthy L, Price JE, Dharmawardhane SF. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells. Breast Cancer Res 2005 7 : R965 74.
33. Kassis J, Moellinger J, Lo H, Greenberg NM, Kim HG, Wells A. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. Clin Cancer Res 1999 5 : 2251 60.